Contents

Search

tecovirimat (TPOXX, ST-246)

Indications: - treatment of smallpox* - available via an expanded access Investigational New Drug (IND) protocol for treatment of monkeypox [3] * advanced as a therapy for smallpox in accordance with the FDA Animal Rule. (FDA-approved July 2018) [2] Dosage: injectable for intravenous administration [3] oral capsule - optimal drug absorption of the oral formulation requires concurrent intake of a high-fat meal (ideally ~600 calories & 25 g of fat) [3] Comparative biology: - 10 mg/kg for 14 days in monkeypox model

General

antiviral agent

Database Correlations

PUBCHEM correlations

References

  1. Grosenbach DW, Honeychurch K, Rose EA Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med 2018; 379:44-53. July 5, 2018 PMID: 29972742 https://www.nejm.org/doi/full/10.1056/NEJMoa1705688
  2. FDA News Release. July 13, 2018 FDA approves the first drug with an indication for treatment of smallpox. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.htm
  3. del Rio C, Malani PN Update on the Monkeypox Outbreak. JAMA. Published online August 11, 2022. PMID: 35951336 https://jamanetwork.com/journals/jama/fullarticle/2795359